Deaths and cardiovascular events in men receiving testosterone

JAMA

Volumn 311, Issue 9, 2014, Pages 962-963

  Jones, T Hugh ^a   Channer, Kevin S ^b  

^a BARNSLEY HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^b SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TESTOSTERONE;

ANDROGEN THERAPY; CARDIOVASCULAR RESPONSE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; HEART INFARCTION; HUMAN; LETTER; MORTALITY; PRESCRIPTION; PRIORITY JOURNAL; SKIN MANIFESTATION; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION;

ANDROPAUSE; HUMANS; MALE; MYOCARDIAL INFARCTION; STROKE; TESTOSTERONE;

EID: 84895494936     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.398     Document Type: Letter

References (5)

1. Vigen R, O'Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310(17):1829-1836.
2. Arver S, Dobs AS, Meikle AW, et al. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men. Clin Endocrinol (Oxf). 1997;47(6):727-737. (Pubitemid 28046562)
3. Carson CC III, Rosano G. Exogenous testosterone, cardiovascular events, and cardiovascular risk factors in elderly men: a review of trial data. J Sex Med. 2012;9(1):54-67.
4. Shores MM, Smith NL, Forsberg CW, Anawalt BD, Matsumoto AM. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab. 2012;97(6):2050-2058.
5. Muraleedharan V, Marsh H, Kapoor D, Channer KS, Jones TH. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol. 2013;169(6):725-733.